hepatocellular carcinoma
Conditions
Interventions
liver tumor biopsy
Sponsors
Department of Gastroenterology and Metabolism, Hiroshima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with advanced HCC in whom the first-line molecular targeted therapy or combined molecular targeted plus immune checkpoint inhibitor therapy begins within four weeks
Exclusion criteria
Exclusion criteria: Patients with allergy to lenvatinib, sorafenib, bevacizumab, atezolizumab, local anesthetics, or analgesics Patients with severe ascites, severe renal failure, severe anemia, severe thrombocytopenia, jaundice, or coagulation disorder Patients who need to take anticoagulants or anti-platelet drugs continuously Patients with severe cognitive dysfunction or psychiatric disorders Patients with severe heart failure Pregnant or nursing mothers, woman who desire to bear children
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histological treatment effects obtained four weeks after the start of molecular targeted drugs | — |
Countries
Japan
Contacts
Public ContactTomokazu Kawaoka
Hiroshima University Hospital Department of Gastroenterology
Outcome results
None listed